ESR1 and breast carcinoma: INPP4B overexpression had little effect on the sensitivity of ER+ breast cancer cells to the SERM afimoxifene/4-hydroxytamoxifen (4-OHT) or the PI3Kα inhibitor alpelisib when cells were grown in monolayer cultures.